Encyclopedia of Opinion
Question
Should birth control be for sale over the counter?
Position1 of 2
Yes, OTC birth control should be for sale
Argument1 of 3

Birth control has long-term health benefits

Aside from reducing the risk of unwanted pregnancies, birth control has a number of health benefits. Women do not always seek out birth control as a contraceptive. Birth control is also used to regulate menstrual cycles, relieve symptoms of PMS, and help reduce the risks of uterine cancer and ovarian cysts.

The argument

Women take birth control for several different reasons. While birth control is effective in pregnancy prevention, there are also many health benefits. Many women use it to regulate their menstrual cycle and reduce symptoms associated with PMS. Birth control is effective in preventing iron deficiency (anemia), bone thinning, acne, ovarian cancers, cysts, and serious infections in the uterus and fallopian tubes. In many countries, including the United States, women must consult a doctor or OB/GYN first before getting a birth control prescription. Many women are without health insurance, and visiting a specialist by paying out of pocket is not always affordable or convenient. By making birth control available over the counter, women would not only have more choices in preventing pregnancy, but for their overall health as well.

Premises

[P1]Birth control offers many health benefits beyond pregnancy prevention — regulating cycles and reducing risks of anaemia, ovarian cancer and infections. [P2] Yet obtaining it requires a doctor's prescription, which is unaffordable or inconvenient for many uninsured women. [P3] Selling it over the counter would give women access to these health benefits as well as contraception. [C] Therefore, because of its long-term health benefits, OTC birth control should be for sale.

Counter-arguments

While it is proven that there are health benefits associated with birth control, there are also many side effects. There are a number of birth control brands that can be prescribed, but some brands are not well suited for certain women based off of their medical history. It would be irresponsible to make birth control available without the consultation of a doctor first. Birth control can come with side effects, such as headaches, vomiting, weight gain, and bleeding in between periods. There are also risk factors for women who are over the age of 35, have a history of cancer, high blood pressure, heart attacks, and blood clotting. Birth control is also risky for women who smoke. Because of these factors, it is important to consult a physician before taking any brand of birth control, no matter how healthy an individual may be. While it would be a woman’s responsibility to know their medical history before taking birth control, some women may be unaware of possible health issues, or may be uneducated on how birth control may be risky for them. Making birth control available over the counter may lead to more health problems for women, and in some cases, can be very dangerous.

Rejecting the premises

[Rejecting P1] The benefits listed are real but are not evenly distributed across products, and the argument treats hormonal contraception as a single thing. Reduced ovarian cancer risk and cycle regulation are associated principally with combined oral contraceptives — which are also the formulations carrying the risks that motivate the prescription requirement in the first place. [Rejecting P2] The premise identifies a cost barrier and then proposes a regulatory change, which does not obviously address it. Over-the-counter status removes the consultation but not necessarily the price, and in systems where contraception is covered by insurance only when prescribed, deregulation can raise the out-of-pocket cost rather than lower it. [Rejecting P3] The counter-argument on record sets out why the consultation is not a formality: combined pills are contraindicated with a history of blood clots, certain cancers, migraine with aura, uncontrolled hypertension, and in smokers over 35, and a user may not know which of these applies to her. Product choice among available formulations also depends on that history. [Rejecting C] The argument would be stronger drawn more narrowly, since the risk profile it needs to escape belongs to the oestrogen-containing products specifically, and progestin-only formulations — which is where over-the-counter approval has in fact been granted — do not carry it. As stated, the conclusion is broader than the premises support.